Search

Your search keyword '"Manai, Chiara"' showing total 16 results
Start Over Author "Manai, Chiara"
16 results on '"Manai, Chiara"'

1. Angioside: The role of Angiogenesis and Hypoxia in Lung Neuroendocrine Tumours According to Primary Tumour Location in Left or Right Parenchyma

Author

La Salvia, Anna, primary, Carletti, Raffaella, additional, Verrico, Monica, additional, Feola, Tiziana, additional, Puliani, Giulia, additional, Bassi, Massimiliano, additional, Sesti, Franz, additional, Pernazza, Angelina, additional, Mazzilli, Rossella, additional, Lamberti, Giuseppe, additional, Siciliani, Alessandra, additional, Mancini, Massimiliano, additional, Manai, Chiara, additional, Venuta, Federico, additional, Ibrahim, Mohsen, additional, Tomao, Silverio, additional, D’Amati, Giulia, additional, Di Gioia, Cira, additional, Giannetta, Elisa, additional, Cappuzzo, Federico, additional, and Faggiano, Antongiulio, additional

Published
2022
Full Text
View/download PDF

2. Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial.

Author

Sartore-Bianchi, Andrea, primary, Pietrantonio, Filippo, additional, Lonardi, Sara, additional, Mussolin, Benedetta, additional, Rua, Francesco, additional, Fenocchio, Elisabetta, additional, Amatu, Alessio, additional, Corallo, Salvatore, additional, Manai, Chiara, additional, Tosi, Federica, additional, Manca, Paolo, additional, Daniel, Francesca, additional, Torri, Valter, additional, Vanzulli, Angelo, additional, Cappello, Giovanni, additional, Marchiò, Caterina, additional, Sapino, Anna, additional, Marsoni, Silvia, additional, Siena, Salvatore, additional, and Bardelli, Alberto, additional

Published
2021
Full Text
View/download PDF

3. Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors

Author

Fucà, Giovanni, primary, Corti, Francesca, additional, Ambrosini, Margherita, additional, Intini, Rossana, additional, Salati, Massimiliano, additional, Fenocchio, Elisabetta, additional, Manca, Paolo, additional, Manai, Chiara, additional, Daniel, Francesca, additional, Raimondi, Alessandra, additional, Morano, Federica, additional, Corallo, Salvatore, additional, Prisciandaro, Michele, additional, Spallanzani, Andrea, additional, Quarà, Virginia, additional, Belli, Carmen, additional, Vaiani, Marta, additional, Curigliano, Giuseppe, additional, Cremolini, Chiara, additional, De Braud, Filippo, additional, Di Bartolomeo, Maria, additional, Zagonel, Vittorina, additional, Lonardi, Sara, additional, and Pietrantonio, Filippo, additional

Published
2021
Full Text
View/download PDF

4. Outcome of patients with colorectal cancer undergoing lung metastases resection: a single-institution retrospective analysis

Author

Mammana, Marco, Bergamo, Francesca, Procaccio, Letizia, Schiavon, Marco, Loupakis, Fotios, Lonardi, Sara, Manai, Chiara, Schirripa, Marta, Fassan, Matteo, Dei Tos, Angelo Paolo, Calabrese, Fiorella, Rea, Federico, and Zagonel, Vittorina

Subjects
Adult, Aged, 80 and over, Male, Proto-Oncogene Proteins B-raf, KRAS mutations, Lung Neoplasms, Genotype, Metastasectomy, lung metastases, Middle Aged, Prognosis, Colorectal cancer, Disease-Free Survival, metastasectomy, Proto-Oncogene Proteins p21(ras), Treatment Outcome, Humans, Female, Postoperative Period, Neoplasm Recurrence, Local, Colorectal Neoplasms, Pneumonectomy, Aged, Proportional Hazards Models
Abstract

This study was undertaken to review a single-institution cohort of patients with metastatic colorectal cancer undergoing lung resection after a multidisciplinary evaluation and to investigate the main prognostic factors for survival.Medical records of 129 patients undergoing lung metastasectomy for colorectal cancer with curative intent from 2001 to 2017 were reviewed. Tissue samples from the primary tumor were analyzed with a multiplex genotyping system for the detection of mutations inPostoperative morbidity and mortality were 13.2% and 0%, respectively. At a median follow-up time of 62.5 months, median overall survival was 90.5 months and median relapse-free survival was 42.8 months. Multivariable analysis for overall survival identified synchronous versus metachronous metastatic presentation as the only prognostic factor, whereas relapse-free survival was independently associated with synchronous versus metachronous metastatic presentation, number of metastases, and postoperative chemotherapy.This study shows particularly favorable survival outcomes for patients undergoing lung metastasectomy. The validity of some of the main prognostic factors was confirmed and a positive effect of postoperative chemotherapy on relapse-free survival was shown. Contrary to other reports, the presence of

Published
2020

6. Observational retrospective evaluation of treatment with liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic cancer patients: An Italian large real-world analysis.

Author

Pellino, Antonio, primary, Manai, Chiara, additional, Merz, Valeria, additional, Scartozzi, Mario, additional, Milella, Michele, additional, De Vita, Ferdinando, additional, Antonuzzo, Lorenzo, additional, Zichi, Clizia, additional, Satolli, Maria Antonietta, additional, Panebianco, Michele, additional, Noventa, Silvia, additional, Giordano, Guido, additional, Nappo, Floriana, additional, Zecchetto, Camilla, additional, Puzzoni, Marco, additional, Vaccaro, Vanja, additional, Pappalardo, Annalisa, additional, Giommoni, Elisa, additional, Melisi, Davide, additional, and Lonardi, Sara, additional

Published
2020
Full Text
View/download PDF

8. Clinical impact of neutropenia and febrile neutropenia in mCRC pts treated with FOLFOXIRI/bevacizumab (bev): A pooled analysis of TRIBE and TRIBE2 studies.

Author

Rossini, Daniele, primary, Sbrana, Andrea, additional, Bergamo, Francesca, additional, Manai, Chiara, additional, Santini, Daniele, additional, Ghidini, Michele, additional, Antoniotti, Carlotta, additional, Moretto, Roberto, additional, Marmorino, Federica, additional, Urbano, Federica, additional, Ronzoni, Monica, additional, Noventa, Silvia, additional, Randon, Giovanni, additional, Carlomagno, Chiara, additional, Latiano, Tiziana Pia, additional, Cordio, Stefano Sergio, additional, Granetto, Cristina, additional, Cremolini, Chiara, additional, Falcone, Alfredo, additional, and Antonuzzo, Andrea, additional

Published
2019
Full Text
View/download PDF

9. Role of the oncological-multidimensional prognostic index in older patients with metastatic colorectal cancer treated in a real-world setting.

Author

Procaccio, Letizia, primary, Brunello, Antonella, additional, Fiduccia, Pasquale, additional, Lettiero, Annunziata, additional, Tierno, Giuseppina, additional, Pusole, Grazia, additional, Bergamo, Francesca, additional, Schirripa, Marta, additional, Manai, Chiara, additional, Zagonel, Vittorina, additional, and Lonardi, Sara, additional

Published
2019
Full Text
View/download PDF

10. Immunotherapy in Gastrointestinal Cancers

Author

Procaccio, Letizia, Schirripa, Marta, Fassan, Matteo, Vecchione, Loredana, Bergamo, Francesca, Prete, Alessandra Anna, Intini, Rossana, Manai, Chiara, Dadduzio, Vincenzo, Boscolo, Alice, Zagonel, Vittorina, and Lonardi, Sara

Subjects
Article Subject
Abstract

Gastrointestinal cancers represent a major public health problem worldwide. Immunotherapeutic strategies are currently under investigation in this setting and preliminary results of ongoing trials adopting checkpoint inhibitors are striking. Indeed, although a poor immunogenicity for GI has been reported, a strong biological rationale supports the development of immunotherapy in this field. The clinical and translational research on immunotherapy for the treatment of GI cancers started firstly with the identification of immune-related mechanisms possibly relevant to GI tumours and secondly with the development of immunotherapy-based agents in clinical trials. In the present review a general overview is firstly provided followed by a focus on major findings on gastric, colorectal, and hepatocellular carcinomas. Finally, pathological and molecular perspectives are provided since many efforts are ongoing in order to identify possible predictive biomarkers and to improve patients’ selection. Many issues are still unsolved in this field; however, we strongly believe that immunotherapy might positively affect the natural history of a subgroup of GI cancer patients improving outcome and the overall quality of life.

Published
2017
Full Text
View/download PDF

11. Outcome of patients with colorectal cancer undergoing lung metastases resection: a single-institution retrospective analysis

Author

Mammana, Marco, Bergamo, Francesca, Procaccio, Letizia, Schiavon, Marco, Loupakis, Fotios, Lonardi, Sara, Manai, Chiara, Schirripa, Marta, Fassan, Matteo, Dei Tos, Angelo Paolo, Calabrese, Fiorella, Rea, Federico, and Zagonel, Vittorina

Abstract

Introduction: This study was undertaken to review a single-institution cohort of patients with metastatic colorectal cancer undergoing lung resection after a multidisciplinary evaluation and to investigate the main prognostic factors for survival.Methods: Medical records of 129 patients undergoing lung metastasectomy for colorectal cancer with curative intent from 2001 to 2017 were reviewed. Tissue samples from the primary tumor were analyzed with a multiplex genotyping system for the detection of mutations in RASand BRAFgenes. Survival analyses were carried out by the Kaplan-Meier method. Univariate and multivariable analyses were performed using the log-rank test and the Cox regression model.Results: Postoperative morbidity and mortality were 13.2% and 0%, respectively. At a median follow-up time of 62.5 months, median overall survival was 90.5 months and median relapse-free survival was 42.8 months. Multivariable analysis for overall survival identified synchronous versus metachronous metastatic presentation as the only prognostic factor, whereas relapse-free survival was independently associated with synchronous versus metachronous metastatic presentation, number of metastases, and postoperative chemotherapy.Conclusions: This study shows particularly favorable survival outcomes for patients undergoing lung metastasectomy. The validity of some of the main prognostic factors was confirmed and a positive effect of postoperative chemotherapy on relapse-free survival was shown. Contrary to other reports, the presence of KRASmutations was not associated with significant survival differences. Further studies are needed in order to clarify the interactions between molecular, clinical, and pathologic characteristics and treatment-related factors.

Published
2021
Full Text
View/download PDF

13. Angiogenesis inhibitor bevacizumab and symptomatic anal ulcers in metastatic colorectal cancer patients: A single center experience.

Author

Battaglin, Francesca, primary, Bergamo, Francesca, additional, Salmaso, Beatrice, additional, Murgioni, Sabina, additional, Intini, Rossana, additional, Saadeh, Luca, additional, Cavallin, Francesco, additional, Manai, Chiara, additional, Urbano, Federica, additional, Lonardi, Sara, additional, Lacognata, Carmelo, additional, Aliberti, Camillo, additional, Zagonel, Vittorina, additional, Castoro, Carlo, additional, and Scarpa, Marco, additional

Published
2017
Full Text
View/download PDF

15. Multimodality Treatment of Gynecomastia in Patients Receiving Antiandrogen Therapy for Prostate Cancer in the Era of Abiraterone Acetate and New Antiandrogen Molecules

Author

Alesini, Daniele, primary, Iacovelli, Roberto, additional, Palazzo, Antonella, additional, Altavilla, Amelia, additional, Risi, Emanuela, additional, Urbano, Federica, additional, Manai, Chiara, additional, Passaro, Antonio, additional, Magri, Valentina, additional, and Cortesi, Enrico, additional

Published
2012
Full Text
View/download PDF

16. Multimodality treatment of gynecomastia in patients receiving antiandrogen therapy for prostate cancer in the era of abiraterone acetate and new antiandrogen molecules.

Author

Alesini D, Iacovelli R, Palazzo A, Altavilla A, Risi E, Urbano F, Manai C, Passaro A, Magri V, and Cortesi E

Subjects
Abiraterone Acetate, Combined Modality Therapy, Humans, Male, Prostatic Neoplasms complications, Androgen Antagonists adverse effects, Androstadienes therapeutic use, Gynecomastia chemically induced, Gynecomastia therapy, Prostatic Neoplasms drug therapy
Abstract

Gynecomastia is a pathological enlargement of male breasts due to hormonal imbalance and elevation of estrogens at the expense of testosterone. It is very important to diagnose this disease precociously because it can be the expression of different underlying pathologies. Besides genetic, chromosomal or chronic diseases, drugs often represent the principal cause of this hormonal disequilibrium. In the elderly population, antiandrogen therapy for prostate cancer frequently induces gynecomastia, thus negatively affecting the patients' compliance to treatment because of physical and psychological discomfort deriving from this condition; gynecomastia can in fact be associated with severe breast pain, and it can modify how patients see their own body. During the past decades and even today, many different surgical, radiotherapeutic or clinical approaches have been proposed to prevent or treat this hypertrophy. This article focuses on gynecomastia associated with antiandrogen-based hormonal treatment and shortly reviews the currently most often used therapeutic options for preventing and treating this pathology., (Copyright © 2012 S. Karger AG, Basel.)

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results